Abstract
Dysregulation of receptor tyrosine kinases (RTKs) in cancer cells is extremely common. Overexpression of human epidermal growth factor receptor (EGFR/HER) tyrosine kinase is correlated with tumor aetiology, progression and poor prognosis. Their activation is also observed frequently in human cancers. Therefore, RTKs have been identified as important therapeutic targets in oncology. Many therapeutic methods have been developed based on inhibition of EGFR and HER-2. Herein, we will discuss recent progress in the development of EGFR/HER-2 tyrosine kinase inhibitors. We will focus on the design strategies, pharmacological profiles and structure-activity relationships (SARs) of EGFR and HER-2 inhibitors.
Keywords: EGFR, ERBB, HER-2, structure-activity relationship, tyrosine kinase.
Current Medicinal Chemistry
Title:Insight into the Medicinal Chemistry of EGFR and HER-2 Inhibitors
Volume: 21 Issue: 11
Author(s): C. Wang, H. Gao, J. Dong, F. Wang, P. Li and J. Zhang
Affiliation:
Keywords: EGFR, ERBB, HER-2, structure-activity relationship, tyrosine kinase.
Abstract: Dysregulation of receptor tyrosine kinases (RTKs) in cancer cells is extremely common. Overexpression of human epidermal growth factor receptor (EGFR/HER) tyrosine kinase is correlated with tumor aetiology, progression and poor prognosis. Their activation is also observed frequently in human cancers. Therefore, RTKs have been identified as important therapeutic targets in oncology. Many therapeutic methods have been developed based on inhibition of EGFR and HER-2. Herein, we will discuss recent progress in the development of EGFR/HER-2 tyrosine kinase inhibitors. We will focus on the design strategies, pharmacological profiles and structure-activity relationships (SARs) of EGFR and HER-2 inhibitors.
Export Options
About this article
Cite this article as:
Wang C., Gao H., Dong J., Wang F., Li P. and Zhang J., Insight into the Medicinal Chemistry of EGFR and HER-2 Inhibitors, Current Medicinal Chemistry 2014; 21 (11) . https://dx.doi.org/10.2174/0929867320666131119124646
DOI https://dx.doi.org/10.2174/0929867320666131119124646 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Molecule of the Month
Current Topics in Medicinal Chemistry PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Current Topics in Medicinal Chemistry Needle in a Haystack: Targeting Specific Glucuronidases Amid the Human Microbiome
Current Enzyme Inhibition Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design A Study on the Composition and Antioxidant Properties of Avicennia marina Leaf Extract
Current Nutrition & Food Science Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry Design, Synthesis, <i>In Silico</i> and <i>In Vitro</i> Evaluation of Novel Pyrimidine Derivatives as EGFR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Neuronal Histamine and its Receptors: Implication of the Pharmacological Treatment of Obesity
Current Medicinal Chemistry Gender Specific Drug Metabolism of PF-02341066 in Rats — Role of Sulfoconjugation
Current Drug Metabolism Molecular and Biological Functions of Melatonin in Endometrial Cancer
Current Drug Targets SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry State of the Art of Biochemical Markers in Metastatic Bone Disease and the Role of Bisphosphonates as Therapeutic Agents
Current Pharmaceutical Analysis Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Synthesis and Hypoxia Selective Radiosensitization Potential of β-2-FAZA and β-3-FAZL: Fluorinated Azomycin β-Nucleosides
Medicinal Chemistry Current Status of Primary Cytoreductive Surgery for the Treatment of Advanced Epithelial Ovarian Cancer
Current Cancer Therapy Reviews Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance
Current Cancer Drug Targets Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Characterization of Carbonic Anhydrase Isozyme Specific Inhibition by Sulfamated 2-Ethylestra Compounds
Letters in Drug Design & Discovery